Purple Biotech Ltd ADR PPBT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.43
- Day Range
- $1.43–1.54
- 52-Week Range
- $1.35–29.00
- Bid/Ask
- $1.43 / $1.64
- Shares Outstanding
- 932,274.00
- Market Cap
- $1.37M
- Volume/Avg
- 13,522 / 305,690
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.purple-biotech.com
Valuation
|
Metric
|
PPBT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PPBT
Financial Strength
|
Metric
|
PPBT
|
|---|---|
Quick Ratio | 1.40 |
Current Ratio | 1.48 |
Interest Coverage | −445.44 |
Quick Ratio
PPBT
Profitability
|
Metric
|
PPBT
|
|---|---|
Return on Assets (Normalized) | −18.91% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −23.30% |
Return on Assets
PPBT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zbh@@m# | LOCK|@%Hw | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|y&!&s% | LOCK|Wylc | $70B | |||
| argenx SE ADR
ARGX
| LOCK|r%B<rLT | LOCK|wKZ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|CzSX&?C | LOCK|C!btM | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&>Dwkrz | LOCK|?x | $37B | |||
| Moderna Inc
MRNA
| LOCK|!Ng#qLX | LOCK|&q | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|j@!##HTp | LOCK|VmCpW | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|dh?MGZ | LOCK|?q | $23B | |||
| Incyte Corp
INCY
| LOCK|wQ^SFc< | LOCK|!MY | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Y&vrr! | LOCK|w! | $16B |
United States